Digital Therapeutics

Prescription digital therapeutics (PDTs) are health software, available by prescription only, intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient’s health.

PDTs offer significant promise in treating certain conditions and improving access to care, but participants agreed that a new modality requires new approaches to coverage. This brief is intended to help prepare the American health care system to begin covering PDTs.

Host Fred Goldstein invites Jennifer Mathieu, Senior Vice President, Professional & Government Affairs to discuss the Prescription Digital Therapeutics Act, the Medicaid MVPs for Patient Act and other AMCP legislative priorities.

AMCP supports increased access to Prescription Digital Therapeutics (PDTs). PDTs are software-based therapies that deliver clinical benefits to patients, either alone or in combination with other forms of treatment. These therapeutics require a prescription and are subject to oversight by the Food and Drug Administration (FDA). To be approved by the FDA, PDTs must demonstrate both safety and efficacy.

Managed care pharmacy and prescription drug coverage is a growing part of the American health care sector. AMCP launched the annual Access, Affordability, and Outcomes report to raise awareness of the existence, prevalence, and importance of managed care pharmacy.

Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! speaks with Dr. Scott Whittle from Meridian Solutions about the pathways to bringing app-based prescription digital therapeutic solutions to health care.

In June, AMCP hosted the Deep Dive into Prescription Digital Therapeutics Summit, convening expert panelists and attendees from across the industry. Read 10 key takeaway points from the Summit.

A rapidly evolving area of interest is digital therapeutics, evidence-based software interventions used to treat, manage, or as an adjunct treatment for various medical conditions. Here are three reasons why you should attend the Virtual AMCP Summit: Deep Dive into Prescription Digital Therapeutics.

AMCP applauds the introduction of the Access to Prescription Digital Therapeutics Act of 2023 into the Senate and House by a bipartisan group of Senators and Representatives. The bill would authorize coverage of prescription digital therapeutics by Medicare and Medicaid, helping millions of Americans receive innovative care to treat a growing range of conditions and illnesses.

The role of digital therapeutics, software that delivers clinical benefits and prevents, manages, and treats medical conditions, has evolved in the past few years. Explore these resources from AMCP, AMCP Learn, and Journal of Managed Care & Specialty Pharmacy resources to learn more about these innovative therapies.

Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Jennifer Graff, Senior Director of Professional Affairs at AMCP, to discuss trends to be watching regarding digital therapeutics and managed care pharmacy in 2023.